jueves, 8 de abril de 2021

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors - The Lancet Oncology

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors - The Lancet Oncology

No hay comentarios:

Publicar un comentario